Most of the challenges we face in using high-performance computing (HPC) to advance science and healthcare is related to sharing, accessing, and analyzing the massive data that is collected, and making it available to researchers and healthcare professionals.

Today, as we race to make more personalized healthcare a reality, Dell is a part of a program that is targeted to help children with cancer. I did a blog post on this recently, which you can read called, HPC and Cloud Computing Helps Genomics Researchers in Battle Against Pediatric Cancer.

This initiative - the first FDA-approved personalized medicine clinical trial for pediatric cancer - has brought together the Translational Genomics Research Institute (TGen) and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) to work on a better solution.

In the end, it’s all about results. In a recently posted article in HPC Wire titled Targeted Care Through a High-Performance Cloud, Dell’s James Coffin, Ph.D., vice president and general manager of Dell Healthcare and Life Sciences, lays out how these new approaches are already leading to better results. Below is taken from that article:

“The HPC environment and first phase of the cloud infrastructure is already yielding significant benefits.  The project has increased TGen’s gene sequencing and analysis capacity by 1,200 percent and improved collaboration between physicians, genetic researchers, pharmacists and computer scientists involved in the clinical trial. This cloud infrastructure and portal technology is designed to efficiently manage the volume and complexity of that data while making it secure and accessible to many. For this personalized medicine trial to be successful, doctors and researchers will need the ability to interpret their patient’s genomic information into useful knowledge for targeted care both quickly and affordably. With TGen translational knowledge and the Dell high-performance cloud technology, researchers have accelerated the analysis of patient-specific genomic data from several days down to one day, resulting in a significant improvement in time to targeted treatment. For patients with neuroblastoma, this literally means the difference between life and death.”